Related Experiment Video
Updated: Jul 29, 2026

Synthesis and Purification of Iodoaziridines Involving Quantitative Selection of the Optimal Stationary Phase for Chromatography
Published on: May 16, 2014
[Development of an intravesial oxybutynin chloride solution: from formulation to quality control]
A Fratta1, J Bordenave, C Boissinot
1Service de Pharmacie, Hôpital Armand Trousseau, 26, avenue du Docteur Arnold Netter, 75571 Paris Cedex 12.
Abstract:
Intravesical oxybutynin chloride has demonstrated its efficacy in children with neurogenic bladder and urinary incontinence refractory to oral anticholinergic agents. We developed a 205 microg/ml oxybutynin chloride solution in accordance with the specifications of the European Pharmacopeae. To guarantee quality, we assessed and validated formulation, the preparation process, and packaging. The solution was obtained by disolving oxybutynin chloride in 0.9% saline and sterile filtration. The solution was then packaged in syringes. Physical properies for intravesical instillation were met: pH 5.76 +/- 0.03, osmolality 281 mosmol/kg. The unit dose package guarantees sterility of the solution until use. The medication is given by adapting the syringe on the Luer Lock exteremity of the urinary catheter. The solution remains stable up to one month at 4 degrees C.
Related Concept Videos
In Vitro Drug Release Testing: Overview, Development and Validation
In Vitro Drug Dissolution: Compendial Testing Models I
Drug Dissolution: Requirements and Profile Comparison
Clinically Relevant Drug Product Specifications: Methods of Establishment
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

